Complications of progression of CKD

Advances in Chronic Kidney Disease

Volumn 18, Issue 6, 2011, Pages 400-405

  Yang, Min ^a,b,c   Fox, Chester H ^a,b,c   Vassalotti, Joseph ^a,b,c   Choi, Michael ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b NATIONAL KIDNEY FOUNDATION   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CKD; Complications; Primary care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MORTALITY; PRIORITY JOURNAL; REVIEW; VITAMIN D DEFICIENCY;

ANEMIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BONE DISEASES; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D DEFICIENCY;

EID: 81255197659     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.10.001     Document Type: Review

References (62)

1. Gilbertson D.T., Liu J., Xue J.L., et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005, 16:3736-3741.
2. Pereira B.J. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int 2000, 57:351-365.
3. Hsu C.Y., McCulloch C.E., Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002, 13:504-510.
4. Foley R.N., Parfrey P.S. Cardiac disease in chronic uremia: clinical outcome and risk factors. Adv Ren Replace Ther 1997, 4:234-248.
5. Gotloib L., Silverberg D., Fudin R., Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006, 19:161-167.
6. Xue J.L., St.Peter W.L., Ebben J.P., Everson S.E., Collins A.J. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002, 40:1153-1161.
7. Palmer S.C., Navaneethan S.D., Craig J.C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010, 153:23-33.
8. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008, 74:791-798.
9. Chen J., Muntner P., Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004, 140:167-174.
10. Schaeffner E.S., Kurth T., Curhan G.C., et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003, 14:2084-2091.
11. Keane W.F., Kasiske B.L., O'Donnell M.P., Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991, 17:38-42.
12. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
13. Tonelli M. The effect of statins on preservation of kidney function in patients with coronary artery disease. Curr Opin Cardiol 2006, 21:608-612.
14. Strippoli G.F., Navaneethan S.D., Johnson D.W., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336:645-651.
15. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009, 54:810-819.
16. Hsu C.Y., McCulloch C.E., Darbinian J., Go A.S., Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923-928.
17. Sarafidis P.A., Li S., Chen S.C., et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008, 121:332-340.
18. Ritz E. Hypertension and kidney disease. Clin Nephrol 2010, 74(suppl 1):S39-S43.
19. Perry H.M., Miller J.P., Fornoff J.R., et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995, 25:587-594.
20. Pohl M.A., Blumenthal S., Cordonnier D.J., et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027-3037.
21. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
22. Udani S., Lazich I., Bakris G.L. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011, 7:11-21.
23. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
24. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
25. Shulman N.B., Ford C.E., Hall W.D., et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989, 13:I80-I93.
26. Apperloo A.J., de Zeeuw D., de Jong P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997, 51:793-797.
27. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
28. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
29. Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809-2816.
30. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
31. Epstein M. Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. Nat Clin Pract Nephrol 2009, 5:12-13.
32. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
33. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
34. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003, 41:47-55.
35. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
36. Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999, 56:2214-2219.
37. Foley R.N., Parfrey P.S., Harnett J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995, 47:186-192.
38. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
39. Rucker D., Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 2009, 5:287-296.
40. Collins A.J., Ma J.Z., Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000, 20:345-349.
41. Arnlov J., Evans J.C., Meigs J.B., et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005, 112:969-975.
42. Nishizawa Y., Shoji T., Kawagishi T., Morii H. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 1997, 62:S90-S92.
43. Tepel M., van der Giet M., Statz M., Jankowski J., Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003, 107:992-995.
44. Yeun J.Y., Levine R.A., Mantadilok V., Kaysen G.A. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000, 35:469-476.
45. Shlipak M.G., Fried L.F., Crump C., et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107:87-92.
46. Mallamaci F., Tripepi G., Cutrupi S., Malatino L.S., Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005, 67:2330-2337.
47. Shamseddin M.K., Parfrey P.S. Mechanisms of the cardiorenal syndromes. Nat Rev Nephrol 2009, 5:641-649.
48. Levin A., Singer J., Thompson C.R., Ross H., Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996, 27:347-354.
49. Cerasola G., Nardi E., Palermo A., Mule G., Cottone S. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol 2011, 24:1-10.
50. Thadhani R. Is calcitriol life-protective for patients with chronic kidney disease?. J Am Soc Nephrol 2009, 20:2285-2290.
51. Herzog C.A. Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int Suppl 2003, S197-S200.
52. Herzog C.A. Can we prevent sudden cardiac death in dialysis patients?. Clin J Am Soc Nephrol 2007, 2:410-412.
53. Pun P.H., Lehrich R.W., Smith S.R., Middleton J.P. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007, 2:491-500.
54. Sprague S.M. Renal bone disease. Curr Opin Endocrinol Diabetes Obes 2010, 17:535-539.
55. Shimada T., Kakitani M., Yamazaki Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
56. Muntner P., Jones T.M., Hyre A.D., et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 2009, 4:186-194.
57. LaClair R.E., Hellman R.N., Karp S.L., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005, 45:1026-1033.
58. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006, 81:353-373.
59. Covic A., Voroneanu L., Goldsmith D. The effects of vitamin D therapy on left ventricular structure and function-are these the underlying explanations for improved CKD patient survival?. Nephron Clin Pract 2010, 116:c187-c195.
60. Finkelstein F.O., Story K., Firanek C., et al. Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies. Kidney Int 2008, 74:1178-1184.
61. Fox C., Kohn L.S. The importance of patient education in the treatment of chronic kidney disease. Kidney Int 2008, 74:1114-1115.
62. Fox C.H., Voleti V., Khan L.S., Murray B., Vassalotti J. A quick guide to evidence-based chronic kidney disease care for the primary care physician. Postgrad Med 2008, 120:E1-E6.